Confirm that channel exists before you purchase, not after you need it
One in 8 American adults reports using a glucagon-like peptide 1 receptor agonist (GLP-1RA) medication, and prescriptions continue to increase due to these drugs effectiveness in reducing cardiovascular mortality and treating diabetes and obesity
The drugs could produce huge benefits for people with obesity but also present a major cost challenge given the large percentage of the population that is eligible for them, the report said
Piening A, Ebert E, Gottlieb C, Khojandi N, Kuehm LM, Hoft SG, et al
While we await dedicated cardiovascular outcomes trials for Retatrutide, I believe the constellation of metabolic improvements points strongly toward cardioprotection